Engineers Gate Manager LP Takes Position in 10x Genomics, Inc. (NASDAQ:TXG)

Engineers Gate Manager LP purchased a new position in shares of 10x Genomics, Inc. (NASDAQ:TXGGet Rating) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 42,240 shares of the company’s stock, valued at approximately $3,213,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of TXG. D1 Capital Partners L.P. acquired a new position in 10x Genomics during the fourth quarter worth approximately $239,081,000. Sands Capital Management LLC increased its position in 10x Genomics by 92.4% during the first quarter. Sands Capital Management LLC now owns 3,201,394 shares of the company’s stock worth $243,530,000 after purchasing an additional 1,537,427 shares during the last quarter. BlackRock Inc. increased its position in 10x Genomics by 14.2% during the first quarter. BlackRock Inc. now owns 9,156,992 shares of the company’s stock worth $696,572,000 after purchasing an additional 1,138,358 shares during the last quarter. ARK Investment Management LLC increased its position in 10x Genomics by 27.5% during the first quarter. ARK Investment Management LLC now owns 3,391,338 shares of the company’s stock worth $257,979,000 after purchasing an additional 730,472 shares during the last quarter. Finally, Baillie Gifford & Co. increased its position in 10x Genomics by 6.9% during the first quarter. Baillie Gifford & Co. now owns 7,355,764 shares of the company’s stock worth $559,552,000 after purchasing an additional 477,387 shares during the last quarter. Institutional investors and hedge funds own 74.10% of the company’s stock.

Insider Buying and Selling at 10x Genomics

In related news, insider Benjamin J. Hindson sold 1,292 shares of the company’s stock in a transaction dated Tuesday, August 23rd. The shares were sold at an average price of $35.19, for a total transaction of $45,465.48. Following the transaction, the insider now owns 186,246 shares in the company, valued at approximately $6,553,996.74. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, CFO Justin J. Mcanear sold 987 shares of the firm’s stock in a transaction that occurred on Tuesday, August 23rd. The shares were sold at an average price of $35.19, for a total transaction of $34,732.53. Following the completion of the transaction, the chief financial officer now directly owns 58,092 shares of the company’s stock, valued at approximately $2,044,257.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Benjamin J. Hindson sold 1,292 shares of the firm’s stock in a transaction that occurred on Tuesday, August 23rd. The stock was sold at an average price of $35.19, for a total transaction of $45,465.48. Following the transaction, the insider now directly owns 186,246 shares of the company’s stock, valued at $6,553,996.74. The disclosure for this sale can be found here. Insiders have sold 4,994 shares of company stock valued at $175,739 in the last 90 days. 11.08% of the stock is currently owned by company insiders.

10x Genomics Stock Performance

TXG stock opened at $35.90 on Monday. The firm has a 50 day simple moving average of $40.03 and a 200 day simple moving average of $51.19. 10x Genomics, Inc. has a 52 week low of $30.12 and a 52 week high of $187.85.

10x Genomics (NASDAQ:TXGGet Rating) last released its quarterly earnings results on Monday, August 8th. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.17). The firm had revenue of $114.61 million during the quarter, compared to the consensus estimate of $115.89 million. 10x Genomics had a negative net margin of 28.62% and a negative return on equity of 17.77%. The company’s revenue for the quarter was down 1.1% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.10) EPS. On average, sell-side analysts forecast that 10x Genomics, Inc. will post -1.73 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently commented on TXG shares. Canaccord Genuity Group assumed coverage on shares of 10x Genomics in a research report on Monday, July 25th. They set a “buy” rating for the company. The Goldman Sachs Group lowered shares of 10x Genomics from a “neutral” rating to a “sell” rating and dropped their price objective for the stock from $55.00 to $35.00 in a research report on Thursday, August 18th. Bank of America lowered shares of 10x Genomics from a “neutral” rating to an “underperform” rating and set a $35.00 price objective for the company. in a research report on Friday, July 15th. Morgan Stanley dropped their price objective on shares of 10x Genomics from $100.00 to $70.00 and set an “overweight” rating for the company in a research report on Wednesday, August 10th. Finally, Canaccord Genuity Group assumed coverage on shares of 10x Genomics in a research report on Monday, July 25th. They issued a “buy” rating and a $55.00 price objective for the company. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $49.25.

10x Genomics Profile

(Get Rating)

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.

See Also

Want to see what other hedge funds are holding TXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 10x Genomics, Inc. (NASDAQ:TXGGet Rating).

Institutional Ownership by Quarter for 10x Genomics (NASDAQ:TXG)

Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.